Team identifies new target for MM CAR T therapy

In a paper published in Nature Medicine, researchers at Osaka University and colleagues identified activated integrin beta(7) as a new target for a chimeric antigen receptor (CAR) T cell therapy for multiple myeloma, demonstrating that a particular conformation of a cell surface antigen expressed on

Read the full 453 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers